A Study of Azenosertib (ZN-c3) and Niraparib in Subjects With Platinum-Resistant Ovarian Cancer
Public ClinicalTrials.gov record NCT05198804. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 1/2 Dose-Escalation and Dose-Expansion Study of ZN-c3 in Combination With Niraparib and ZN-c3 Monotherapy in Subjects With Platinum-Resistant Ovarian Cancer
Study identification
- NCT ID
- NCT05198804
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 1, Phase 2
- Lead sponsor
- K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc
- Industry
- Enrollment
- 117 participants
Conditions and interventions
Conditions
Interventions
- Azenosertib Drug
- Niraparib Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- Female
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jan 26, 2022
- Primary completion
- Oct 14, 2025
- Completion
- Jan 18, 2026
- Last update posted
- Mar 17, 2026
2022 – 2026
United States locations
- U.S. sites
- 16
- U.S. states
- 11
- U.S. cities
- 15
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Arizona Oncology Associates (Wilmot HOPE) - USOR | Tucson | Arizona | 85711 | — |
| Rocky Mountain Cancer Centers | Aurora | Colorado | 80012 | — |
| University of Colorado | Aurora | Colorado | 80045 | — |
| Mount Sinai Comprehensive Cancer Center | Miami Beach | Florida | 33140 | — |
| Karmanos Cancer Institute | Detroit | Michigan | 48201 | — |
| Spectrum Health System | Grand Rapids | Michigan | 49503 | — |
| Rutgers New Jersey Medical School | Newark | New Jersey | 07103 | — |
| Optimum Clinical Research Group- Women's Oncology | Albuquerque | New Mexico | 87109 | — |
| The Blavatnik Family - Chelsea Medical Center at Mount Sinai | New York | New York | 10011 | — |
| Willamette Valley Cancer Institute and Research Center | Eugene | Oregon | 97401 | — |
| Women and Infants Hospital of Rhode Island | Providence | Rhode Island | 02905 | — |
| Texas Oncology-Fort Worth Cancer Center | Fort Worth | Texas | 76104 | — |
| MD Anderson Cancer Center, Gynecologic Oncology Center | Texas City | Texas | 77030 | — |
| University of Virginia | Charlottesville | Virginia | 22908 | — |
| Virginia Cancer Specialists | Fairfax | Virginia | 22031 | — |
| Virginia Commonwealth University | Richmond | Virginia | 23298 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 6 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT05198804, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Mar 17, 2026 · Synced May 16, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT05198804 live on ClinicalTrials.gov.